# A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed Ovarian Cancer

> **NCT04718376** · PHASE1 · TERMINATED · sponsor: **CSPC ZhongQi Pharmaceutical Technology Co., Ltd.** · enrollment: 56 (actual)

## Conditions studied

- Platinum-resistant Ovarian Cancer

## Interventions

- **DRUG:** Mitoxantrone Hydrochloride Liposome, intravenous injection (IV)

## Key facts

- **NCT ID:** NCT04718376
- **Lead sponsor:** CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-01-12
- **Primary completion:** 2023-05-22
- **Final completion:** 2023-05-22
- **Target enrollment:** 56 (ACTUAL)
- **Why stopped:** The sponsor has adjusted its R\&D strategy.
- **Last updated:** 2024-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04718376

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04718376, "A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed Ovarian Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04718376. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*